Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein

Clinical Chemistry

Volumn 53, Issue 6, 2007, Pages 1053-1060

  Russo, Isabella ^a   Del Mese, Paola ^a   Doronzo, Gabriella ^a   De Salve, Alessandro ^a   Secchi, Mariantonietta ^a   Trovati, Mariella ^a   Anfossi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; 8 (4 CHLOROPHENYLTHIO) CYCLIC GMP; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC NUCLEOTIDE; SERINE; VASODILATOR AGENT; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LIGHT SCATTERING; MALE; OBESITY; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ADULT; BLOOD PLATELETS; CELL ADHESION MOLECULES; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; HUMANS; LIGHT; MALE; MICROFILAMENT PROTEINS; NUCLEOTIDES, CYCLIC; OBESITY; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; SCATTERING, RADIATION; THIONUCLEOTIDES;

EID: 34249879295     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.076208     Document Type: Article

References (40)

1. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002;105:2696-8.
2. McGill HC, McMahan CA, Hardarick EE, Zla̧ske AW, Malcolm GT, Tracy RE, et al. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002;105:2712-8.
3. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndroms: a new worldwide definition. Lancet 2005;366:1059-62.
4. Massberg S, Brand K, Grunar S, Page S, Muller E, Mullar I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196:887-96.
5. Ruggeri ZM. Platelets in atharothrombosis. Nat Med 2002;8:1227-34.
6. Trovati M, Mularoni E, Burzacca S, Ponziani MC, Massucco P, Mattiallo L, et al. Impaired insulin-induced platelet anti-aggregating effect in obesity and in obese NIDDM patients. Diabetes 1995;44:1318-22.
7. Trovati M, Anfossi G. Insulin, insulin-resistance, and platelet function: similarities with insulin effects on cultured smooth muscle cells. Diabetologia 1998;41:609-22.
8. Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diab Complicat 2002;16:35-40.
9. Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabates Care 1998;21:121-6.
10. Anfossi G, Mularoni E, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Impaired platelet sensitivity to the anti-aggregating effects of adenosine in obesity and obese non-insulin-dependent diabetes mellitus. In: Belfiore F, Lorenzi M, Molinatti GM, Porta M eds. Molecular and Cell Biology of Type 2 Diabetes and its Complications, Frontiers in Diabetes Vol. 14, Basel: Karger, 1998:184-7.
11. Anfossi G, Russo I, Massucco P, Mattiello L, Doronzo G, De Salve A, et al. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest 2004;34:482-9.
12. Pfeifer A, Ruth P. Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol 1999;135:105-49.
13. Schwarz UR, Welter U, Eigenthalar M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62:1153-61.
14. Jensen BO, Selheim F, Doskeland SO, Gear ARL, Holmsen H. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood 2004;104:2775-82.
15. Anti M, von Bruhl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, et al. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 2007;109:552-9.
16. Yamanishi J, Kawahara Y, Fukuzaki H. Effect of cyclic AMP on cytoplasmic free calcium in human platelets stimulated by thrombin: direct measurement with quin-2. Thromb Res 1983;32:183-8.
17. Kawahara Y, Yamanishi J, Fukuzaki H. Inhibitory action of guanosine 3′,5′ monophosphate on thrombin-induced calcium mobilization in human platelets. Thromb Res 1984;33:203-9.
18. Horstrup K, Jablonka B, Honig-Liedl P, Just M, Kochslek K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein et Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994;22:21-7.
19. Bearer EL, Prekash JM, Manchester RD, Allan PG. VASP protects actin filaments from gelsolin: an in vitro study with implications for platelet actin reorganizations. Cell Motil Cytoskeleton 2000;47:351-64.
20. Li Z, Xi X, Gu M, Fell R, Ye RD, Eigenthaler M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003;112:77-86.
21. Li Z, Zhang G, Fell R, Han J, Du X. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alphaIIb beta3. Blood 2006;107:965-72.
22. Waldmann R, Nieberding M, Walter U. Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kineses. Eur J Biochem 1987;167:441-8.
23. Butt E, Abel K, Krieger M, Palm D, Hoppe V, Walter U. cAMP- end cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 1994;269:14509-17.
24. Hausar W, Knobeloch KP, Eigenthaler M, Gamberyan S, Krenn V, Geiger J, et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci U S A 1999;96:8120-5.
25. Nolte C, Eigenthalar M, Horstrup K, Honig-Lladl P, Walter U. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elavating platelet inhibitors Biochem Pharmacol 1994;48:1569-75.
26. Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders: the mechanism of "Syndrome X". Am J Hypertens 1993;6:123S-34S.
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-421.
28. Geiger J, Nolte C, Butt E, Sage SO, Walter U. Role of cGMP end cGMP-dependent protein kinase in nitrovesodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc Natl Acad Sci U S A 1992;89:1031-5.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-9.
30. Haffner SM, Miettinen H, Stern MP. Homeostasis model in the San Antonio Heart Study. Diabetes Care 1997;20:1087-92.
31. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998;16:895-406.
32. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
33. Dey NB, Boarth NJ, Murphy-Ullrich JE, Chang PL, Prince CW, Lincoln TM. Cyclic GMP-dependant protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells. Circ Res 1998;82:139-46.
34. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The Metabolic Syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
35. Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. Diab Vasc Dis Res 2004;1:68-75.
36. Tardito D, Maine G, Tura GB, Bogetto F, Pioli R, Ravizza L, et al. The cAMP-dependent protein kinase substrate Rap1 in platelets from patients with obsessive compulsive disorder or schizophrenia. Eur Neuropsychopharmacol 2001;11:221-5.
37. Abel K, Mieskes G, Walter U. Dephosphorylation of the focal adhesion protein VASP in vitro and in intact human platelets. FEBS Lett 1995;370:184-8.
38. Isomaa B, Almgren p, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
39. Vinik AI, Erbes T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diab Cere 2001;24:1476-85.
40. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diab Care 2003;26:2181-8.